Abstract
Purpose
Previous studies show that fentanyl pectin nasal spray (FPNS) rapidly provides clinically meaningful pain relief in the treatment of breakthrough cancer pain (BTCP). This study assessed the long-term tolerability, acceptability and consistency of effect of FPNS in patients with BTCP.
Methods
Patients (new and rolled over from earlier controlled studies) with cancer experiencing one to four episodes per day of BTCP whilst taking ≥60 mg/day of morphine (or equivalent) given orally for cancer pain entered an open-label 16-week safety study. Safety and tolerability were assessed by adverse events (AEs), adverse drug reactions (ADRs), withdrawal due to AEs and by nasal assessments. Acceptability assessments included ratings of overall satisfaction with each treated episode and ease of use and convenience of FPNS. Additional rescue medication and dose stability were used to evaluate the consistency of effect.
Results
Four hundred three patients were included in the safety and intent-to-treat analysis (42,227 episodes), 356 entered the treatment phase and 110 completed 16 weeks. Overall, 24.6% of 403 patients reported treatment-related treatment-emergent AEs that were generally mild/moderate and typical of opioids; 20 patients discontinued treatment due to an AE (9 were ADRs). Nasal assessments revealed no clinically significant effects; 94% of FPNS-treated episodes required no additional rescue medication. More than 90% of patients did not have to increase their dose during the study. Patients reported overall satisfaction with FPNS for 90.1% of episodes. At week 12, 96.9% of patients were satisfied with the ease of use and 97.9% with the convenience of FPNS.
Conclusions
FPNS was generally well tolerated and well accepted for the treatment of BTCP, and doses remained stable over the 4-month study period.
Similar content being viewed by others
References
Bennett DS, Burton AW, Fishman S et al (2005) Consensus panel recommendations for the assessment and management of breakthrough pain, part 2: management. Pharm Ther 30(6):354–361
Brennan F (2007) Palliative care as an international human right. J Pain Symptom Manage 33(5):494–499
Caraceni A, Martini C, Zecca E et al (2004) Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med 18(3):177–183
Cherny NI, Baselga J, de Conno F, Radbruch L (2010) Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 21(3):615–626
Collins SL, Faura CC, Moore RA, McQuay HJ (1998) Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 16(6):388–402
Dale O, Hjortkjaer R, Kharasch ED (2002) Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 46(7):759–770
Davies AN, Broadley K, Beighton D (2001) Xerostomia in patients with advanced cancer. J Pain Symptom Manage 22(4):820–825
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13(4):331–338
Davies AN, Vriens J, Kennett A, McTaggart M (2008) An observational study of oncology patients’ utilization of breakthrough pain medication. J Pain Symptom Manage 35(4):406–411
Fallon M, Gatti A, Davies AN et al (2009) Efficacy, safety and patient acceptability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multicentre, double-blind, double-dummy, multiple-crossover study. Eur J Cancer Supp 7:15
Illum L (2003) Nasal drug delivery—possibilities, problems and solutions. J Control Release 87(1–3):187–198
Mercadante S, Radbruch L, Caraceni A et al (2002) Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94(3):832–839
Miaskowski C, Dodd MJ, West C et al (2001) Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol 19(23):4275–4279
Petzke F, Radbruch L, Zech D, Loick G, Grond S (1999) Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage 17(6):391–401
Portenoy R, Bruns D, Shoemaker B, Shoemaker S (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 6:97–108
Portenoy RK, Burton A, Gabrail N (2010) A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 151(3):617–624
Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41(3):273–281
Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81(1–2):129–134
Svendsen KB, Andersen S, Arnason S et al (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9(2):195–206
Walker G, Wilcock A, Manderson C, Weller R, Crosby V (2003) The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med 17(2):219–221
Watts P, Smith A (2009) PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv 6(5):543–552
Acknowledgements
This study was sponsored by Archimedes Development Ltd. The authors wish to acknowledge i3Research, which conducted the study, and the technical and editorial support provided by Anita Chadha-Patel and ApotheCom.
Conflict of interest
None of the authors has any financial relationships to disclose related to this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Radbruch, L., Torres, L.M., Ellershaw, J.E. et al. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer 20, 565–573 (2012). https://doi.org/10.1007/s00520-011-1124-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-011-1124-x